lewis lung carcinoma 392 llc cells (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
lewis lung carcinoma 392 llc cells
Lewis Lung Carcinoma 392 Llc Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 7122 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lewis+lung+carcinoma+392+llc+cells/MDCK/pm41985745-234-43-49
Average 99 stars, based on 7122 article reviews
Lewis Lung Carcinoma 392 Llc Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 7122 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lewis+lung+carcinoma+392+llc+cells/MDCK/pm41985745-234-43-49
Average 99 stars, based on 7122 article reviews
lewis lung carcinoma 392 llc cells - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Expressing:Article Title: A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Cell Culture:Article Title: A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Modification:Article Title: A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. |